RISK FACTORS OF CARDIOVASCULAR DISEASE IN PATIENTS WITH TYPE 2 DIABETES AND NON-ALCOHOLIC FATTY LIVER DISEASE

Authors

  • Chernyaeva A. O. SI "V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine", Kharkiv

DOI:

https://doi.org/10.21856/j-PEP.2014.1.01

Keywords:

type 2 diabetes mellitus, non-alcoholic fatty liver disease, complications, prevalence, cardiovascular diseases

Abstract

It was studied the correlation of cardiovascular disease with non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (DM). It was found that among patients with type 2 diabetes with NAFLD hypertension observed in 78.9 %, and in patients with type 2 diabetes without NAFLD — in 54% of cases. In patients with myocardial infarction is a significant increase in alanine aminotransferase (ALT) as compared to patients without myocardial infarction. Non-alcoholic fatty liver disease in patients with type 2 diabetes accompanied by the obesity, hypertension, disorders of lipid and carbohydrate metabolism.

References

Charlton M. Clin Gastroenterol Hepatol 2004; 2:1048-1058.

De Alwis NM, Day CP. J Hepatol 2008; 48(1):104-112.

Vuppalanchi R, Chalasani N. Hepatology 2009; 49:306-317.

Brea A, Mosquera D, Martin E, et al. Arterioscler Thromb Vasc Biol 2005; 25:1045-1050.

Bogomolov PO. Shul’pekova JuO. Bolezni pecheni i zhelchevyvodjashhih putej, Moskva, 2005: 205-216.

Diehl AM. Amer J Physiol 2002; 282(1):1-5.

Butrova SA. Rus Med Zhurn 2001; 9:56-60.

Ivashkin VT, Maevskaja MV. Ros Zhurn Gastrojenterologii, Gepatologii, Koloproktologii 2010; 20(1):4-13.

Adams LA, Lymp JF, Sauver JSt, et al. Gastroenterology 2005; 129:113-121.

JAMA 2001; 285:2486-2497.

Marchesini G, Brizi M, Morselli-Labate AM, et al. Amer J Med 1999; 107(5):450-455.

Bogomolov PO, Shul’pekova JuO. Klin Perspektivy Gastrojenterologii i Gepatologii 2004; 3:20-26.

Korneeva ON. Klinicheskie varianty metabolicheskogo sindroma, Moskva, 2007: 161 p.

Korneeva ON, Drapkina OM, Bueverov AO, Ivashkin VT. Klin Perspektivy Gastrojenterologii i Gepatologii 2005; 4:24-27.

Marchesini G, Bugianesi E, Forlani G, et al. Hepatology 2003; 37:217-231.

Scheen AJ, Luyckx FH. Acta Clin Belg 2003; 58(2):81-91.

Matteoni CA, Younossi ZM, Gramlich T, et al. Gastroenterology 1999; 116:1413-1419.

Laxmi MV, Mouen K, Naga C. Curr Gastroenterol Rep 2009; 11:50-55.

Bueverov AO, Maevskaja MV, Shirokova EN. Nealkogol’nyj steatogepatit, Moskva, 2005: 16 p.

Dixon JB. Gastroenterology 2001; 91:100.

Kovalenko VN, Nesukaj EG, Dolzhenko MN, Gorbas’ IM. Profilaktika serdechno-sosudistyh zabolevanij: populjacionnaja strategija i individualizirovannye programmy, Kiev, 2013: 96 p.

Cortez-Pinto H, Camilo ME, Baptista A, et al. Clin Nutr 1999; 18(6):353-358.

Kovalenko LI, Makovskaja LI, Levenko IE, et al. Probl Starenija i Dolgoletija 2012; 21:69-70.

Kunde SS, et al. Hepatology 2005; 42(4):650-656.

Mit’kov VV, Sandrikov VA. Klinicheskoe rukovodstvo po ul’trazvukovoj diagnostike, Moskva, 1998: 360 p.

Joseph AE, Saverymuttu SH, Al-Sam S, et al. Clin Radiol 1991; 43:26-31.

Mottin CC, Moretto M, Padoin AV, et al. Obes Surg 2004; 14:635-637.

Babak OJa, Kolesnikova EV. Sovremennaja Gastrojenterologija 2006; 4(30):8-12.

Bedogni G, Miglioli L, Masutti F, et al. Hepatology 2007; 46(5):1387-1391.

Avdeeva MG, et al. Infekcionnye Bolezni 2009; 2:22-25.

Kannel WB, Cuppels LA, Ramaswami R, et al. J Clin Epidemiol 1991; 44(2):183-190.

Downloads

Published

2014-03-12

How to Cite

Chernyaeva, A. O. (2014). RISK FACTORS OF CARDIOVASCULAR DISEASE IN PATIENTS WITH TYPE 2 DIABETES AND NON-ALCOHOLIC FATTY LIVER DISEASE. Problems of Endocrine Pathology, 47(1), 7-14. https://doi.org/10.21856/j-PEP.2014.1.01

Issue

Section

CLINICAL ENDOCRINOLOGY